

Format of Quarterly Compliance Report on Corporate Governance

Name of the Company : M/s. Bliss GVS Pharma Limited
CIN : L24230MH1984PLC034771
BSE CODE : 506197
Quarter ending on : 01st July, 2015 to 30th September, 2015

Particulars	Clause of Listing Agreement	Compliance Status Yes/No/N.A	Remarks
II. Board of Directors	49 (II)		
(A) Composition of Board	49 (IIA)	YES*	Total No. of Directors-6 Executive Directors-3 Non-Executive Director-1 Independent Directors-2
(B) Independent Directors	49 (IIB)	YES	
(C) Non-executive Directors' compensation & disclosures	49 (IIC)	YES	
(D) Other provisions as to Board and Committees	49 (IID)	YES	
(E) Code of Conduct	49 (IIE)	YES	
(F) Whistle Blower Policy	49 (IIF)	YES	
III. Audit Committee	49 (III)		
(A) Qualified & Independent Audit Committee	49 (IIIA)	YES	
(B) Meeting of Audit Committee	49 (IIIB)	YES	
(C) Powers of Audit Committee	49 (IIIC)	YES	
(D) Role of Audit Committee	49 (IIID)	YES	
(E) Review of Information by Audit Committee	49 (IIIE)	YES	
IV. Nomination and Remuneration Committee	49 (IV)	YES	
V. Subsidiary Companies	49 (V)	N.A	
VI. Risk Management	49 (VI)	YES	
VII. Related Party Transactions	49 (VII)	YES	
VIII. Disclosures	49 (VIII)		
(A) Related party transactions	49 (VIIIA)	YES	There are related party transactions in this quarter.
(B) Disclosure of Accounting Treatment	49 (VIIIB)	YES	On a going concern basis and as per accounting standards.
(C) Remuneration of Directors	49 (VIII C)	YES	Details are part of disclosures in the Annual Report. The non-executive Directors are only receiving sittings.
(D) Management	49 (VIII D)	YES	Disclosed in the Annual Report 2014-15.
(E) Shareholders	49 (VIII E)	YES	There was no new

			appointment for this quarter.
(F) Proceeds from public issues, rights issue, preferential issues, etc.	49 (VIII F)	N.A	
IX. CEO/CFO Certification	49 (IX)	YES	Disclosed in the Annual Report 2014-15.
X. Report on Corporate Governance	49 (X)	YES	Disclosed in the Annual Report 2014-15.
XI. Compliance	49 (XI)	YES	Disclosed in the Annual Report 2014-15.

Note: * The Chairman and Independent Director resigned on 29th May, 2015. The Company is in process to appoint independent director and it have shortlisted the same. In forthcoming Board Meeting the company shall appoint. Hence it is going to be second quarter as per standard operating procedure of Stock Exchange, the company need to appoint independent director to comply the same.

For **BLISS GVS PHARMA LIMITED**

VIPUL THAKKAR
CHIEF FINANCIAL OFFICER